Home > Neurology > EAN 2022 > Migraine > Over a third of patients responds late to CGRP antibodies

Over a third of patients responds late to CGRP antibodies

Presented By
Dr Cinzia Aurilia, University of Florence, Italy
EAN 2022
Calcitonin gene-related peptide (CGRP) monoclonal antibodies elicited a late therapeutic response in over one-third of migraine patients who were initially considered non-responders at 12 weeks, in a real-life study with 912 participants. The authors advocate to extend the efficacy evaluation of CGRP inhibitors to 6 months. Migraine patients usually have an early response, within 12 weeks of treatment, to CGRP inhibitors. A real-life cohort study, presented by Dr Cinzia Aurilia (University of Florence, Italy), was set up to establish the late response rate (beyond 12 weeks of treatment) in all consecutive patients who were treated with a CGRP inhibitor for ≄12 months over a 3-year period [1]. Included were 912 patients from 16 specialised centres with either chronic migraine (CM; n=690) or high-frequency episodic migraine (HFEM; n=222). Patients were treated with erenumab (n=789), fremanezumab (n=65), or galcanezumab (n=58). The primary en...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on